Plain-English translation of NCT05579366 on ClinicalTrials.gov β Β· Source last updated Β· Translation generated Β· How we translate trials
Phase 1/2 β A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing a new cancer drug called Rinatabart Sesutecan (also known as or GEN1184) to see if it can help people with advanced solid tumors, including ovarian, endometrial, breast, lung, and other cancers. The medication is designed to target cancer cells that have a specific marker called folate receptor alpha. Researchers are testing this treatment both by itself and in combination with other well-known cancer drugs to understand how safe it is and how well it works.
Many patients with advanced cancers like ovarian, endometrial, and triple-negative breast cancer run out of treatment options or develop resistance to standard therapies. This medication offers a new approach by targeting a specific feature on cancer cells, which may help patients whose tumors have limited other options.
You likely qualify ifβ¦
You likely don't qualify ifβ¦
You will receive the new medication either as a single treatment or combined with another cancer drug, depending on which part of the trial you join. You will visit the clinic regularly for infusions, blood work, imaging scans, and check-ups to monitor how you're responding and watch for side effects. You will continue treatment until your cancer progresses, you experience unacceptable side effects, or your doctor decides it's no longer helping β which could be weeks, months, or longer depending on how your body responds.
AI-generated summary from trial data Β· Aug 15, 2026 Β· Not medical advice
United States